Titel

Merkliste
1 Ergebnisse

PRODIGE 59-DURIGAST trial: A randomised phase II study eval..:

Evrard, Camille ; Louvet, Christophe ; Hajbi, Farid El...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.dld.2020.11.036. , 2021

Link: https://hal.science/hal-03102304

RT Journal
T1 <Title>PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer</Title>

UL https://suche.suub.uni-bremen.de/peid=base-ftinserm:oai:HAL:hal-03102304v1&Exemplar=1&LAN=DE
				
A1 Evrard, Camille
A1 Louvet, Christophe
A1 Hajbi, Farid El
A1 Fiore, Frédéric Di
A1 Malicot, Karine Le
A1 Aparicio, Thomas
A1 Bouché, Olivier
A1 Laurent-Puig, Pierre
A1 Bibeau, Frédéric
A1 Lecomte, Thierry
A1 Lièvre, Astrid
A1 Guimbaud, Rosine
A1 Kim, Stefano
A1 Zaanan, Aziz
A1 Sokol, Harry
A1 Chibaudel, Benoist
A1 Desrame, Jérome
A1 Pierre, Sabrina
A1 Gonzalez, Daniel
A1 Lepage, Come
A1 Tougeron, David
PB HAL CCSD; Elsevier
YR 2021
K1 Adenocarcinoma
K1 Chemotherapy
K1 Gastric cancer
K1 Immune checkpoint inhibitors
K1 [SDV.CAN]Life Sciences [q-bio]/Cancer
K1 [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology
JF info:eu-repo/semantics/altIdentifier/doi/10.1016/j.dld.2020.11.036
LK http://dx.doi.org/https://hal.science/hal-03102304
DO https://hal.science/hal-03102304
SF ELIB - SuUB Bremen

Export

RefWorks (nur Desktop-Version!)
Flow (Zuerst in Flow einloggen, dann importieren)